Signal transducer and activator of transcription 3: A year in review

Current Opinion in Hematology

Volumn 23, Issue 1, 2016, Pages 23-27

  Forbes, Lisa R ^a   Milner, Josh ^b   Haddad, Elie ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Autoimmunity; Immunodeficiency; Job's syndrome; Lymphoproliferation; Signal transducer and activator of transcription 3; Th17 cells

Indexed keywords

INTERLEUKIN 17; STAT3 PROTEIN; ANTIBODY;

ALLERGY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL INFECTION; CANDIDIASIS; CYTOTOXICITY; DISEASE COURSE; DISEASES; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; LOSS OF FUNCTION MUTATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOLECULAR PATHOLOGY; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS REACTIVATION; ANIMAL; BIOSYNTHESIS; GENETICS; HYPERSENSITIVITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFECTION; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; MICROBIOLOGY; MUTATION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; VIROLOGY;

ANIMALS; ANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOLOGIC MEMORY; INFECTION; INTERLEUKIN-17; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; MUTATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; TH17 CELLS;

EID: 84952629424     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000206     Document Type: Review

References (42)

1. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368:161-170.
2. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 2015; 194:21-27.
3. Harris TJ, Grosso JF, Yen HR, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179:4313-4317.
4. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997; 94:3801-3804.
5. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14:736-746.
6. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366:1905-1913.
7. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357:1608-1619.
8. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448:1058-1062.
9. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-776.
10. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008; 205:1543-1550.
11. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008; 205:1551-1557.
12. Renner ED, Rylaarsdam S, Anover-Sombke S, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 2008; 122:181-187.
13. Okada S, Markle JG, Deenick EK, et al. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015; 349:606-613.
14. Bandaru A, Devalraju KP, Paidipally P, et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol 2014; 44:2013-2024.
15. Wilson RP, Ives ML, Rao G, et al. STAT3 is a critical cell-intrinsic regulator of human unconventional T cell numbers and function. J Exp Med 2015; 212:855-864.
16. Siegel AM, Heimall J, Freeman AF, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 2011; 35:806-818.
17. Chandesris MO, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine 2012; 91:e1-e19.
18. Cui W, Liu Y, Weinstein JS, et al. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 2011; 35:792-805.
19. Ichii H, Sakamoto A, Hatano M, et al. Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells. Nat Immunol 2002; 3:558-563.
20. Parmigiani A, Pallin MF, Schmidtmayerova H, et al. Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells. Hum Immunol 2011; 72:115-123.
21. Strengell M, Sareneva T, Foster D, et al. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 2002; 169:3600-3605.
22. Zeng R, Spolski R, Casas E, et al. The molecular basis of IL-21-mediated proliferation. Blood 2007; 109:4135-4142.
23. Ives ML, Ma CS, Palendira U, et al. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function. J Allergy Clin Immunol 2013; 132:400-411.
24. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J Clin Immunol 2005; 25:534-540.
25. Zhu S, Phatarpekar PV, Denman CJ, et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood 2014; 124:403-411.
26. Avery DT, Ma CS, Bryant VL, et al. STAT3 is required for IL-21-induced secretion of IgE from human naive B cells. Blood 2008; 112:1784-1793.
27. Deenick EK, Avery DT, Chan A, et al. Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibodysecreting plasma cells. J Exp Med 2013; 210:2739-2753.
28. Siegel AM, Stone KD, Cruse G, et al. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J Allergy Clin Immunol 2013; 132:1388-1396.
29. Boos AC, Hagl B, Schlesinger A, et al. Atopic dermatitis, STAT3-and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014; 69:943-953.
30. Laurence A, Amarnath S,Mariotti J, et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 2012; 37:209-222.
31. Durant L, Watford WT, Ramos HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010; 32:605-615.
32. de Koning JP, Soede-Bobok AA, Ward AC, et al. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colonystimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 2000; 19:3290-3298.
33. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120:3048-3057.
34. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40:713-715.
35. Willson TA, Kuhn BR, Jurickova I, et al. STAT3 genotypic variation and cellular STAT3 activation and colon leukocyte recruitment in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012; 55:32-43.
36. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491:119-124.
37. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014; 46:812-814.
38. Haapaniemi EM, Kaustio M, Rajala HL, et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 2015; 125:639-648.
39. Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015; 125:591-599.
40. Haddad E. STAT3: too much may be worse than not enough! Blood 2015; 125:583-584.
41. Kanai T, Jenks J, Nadeau KC. The STAT5b pathway defect and autoimmunity. Front Immunol 2012; 3:234.
42. Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front Immunol 2014; 5:58.